{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Diffuse+Parenchymal+Lung+Disease&page=22",
    "query": {
      "condition": "Diffuse Parenchymal Lung Disease",
      "page": 22
    },
    "page_size": 10
  },
  "pagination": {
    "page": 22,
    "page_size": 10,
    "total_count": 597,
    "total_pages": 60,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Diffuse+Parenchymal+Lung+Disease&page=23&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Diffuse+Parenchymal+Lung+Disease&page=21&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T07:12:03.869Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05567133",
      "title": "Risk Indicators of Sarcoidosis Evolution-Unified Protocol",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Sarcoidosis, Pulmonary"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2023-01-10",
      "completion_date": "2030-03-30",
      "has_results": false,
      "last_update_posted_date": "2026-01-08",
      "last_synced_at": "2026-10-16T07:12:03.869Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Dallas, Texas",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05567133"
    },
    {
      "nct_id": "NCT05892614",
      "title": "Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Interstitial Lung Disease"
      ],
      "interventions": [
        {
          "name": "efzofitimod 450 mg",
          "type": "DRUG"
        },
        {
          "name": "efzofitimod 270 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "aTyr Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2023-10-26",
      "completion_date": "2026-04",
      "has_results": false,
      "last_update_posted_date": "2025-05-07",
      "last_synced_at": "2026-10-16T07:12:03.869Z",
      "location_count": 15,
      "location_summary": "Los Angeles, California • San Diego, California • Miami, Florida + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05892614"
    },
    {
      "nct_id": "NCT02846324",
      "title": "Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPF",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Idiopathic Pulmonary Fibrosis",
        "Hypoxemia"
      ],
      "interventions": [
        {
          "name": "GBT440",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Global Blood Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "45 Years to 80 Years"
      },
      "enrollment_count": 39,
      "start_date": "2016-06",
      "completion_date": "2017-11",
      "has_results": true,
      "last_update_posted_date": "2020-10-20",
      "last_synced_at": "2026-10-16T07:12:03.869Z",
      "location_count": 12,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Denver, Colorado + 9 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02846324"
    },
    {
      "nct_id": "NCT04093024",
      "title": "A Study to Find Out How Nintedanib is Taken up in the Body and How Well it is Tolerated in Children and Adolescents With Interstitial Lung Disease (ILD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lung Diseases, Interstitial"
      ],
      "interventions": [
        {
          "name": "Nintedanib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 39,
      "start_date": "2019-12-03",
      "completion_date": "2022-05-24",
      "has_results": true,
      "last_update_posted_date": "2024-07-09",
      "last_synced_at": "2026-10-16T07:12:03.869Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Indianapolis, Indiana + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04093024"
    },
    {
      "nct_id": "NCT04594707",
      "title": "A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Idiopathic Pulmonary Fibrosis"
      ],
      "interventions": [
        {
          "name": "PRM-151 (Zinpentraxin Alfa)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 117,
      "start_date": "2021-08-30",
      "completion_date": "2023-02-10",
      "has_results": true,
      "last_update_posted_date": "2024-05-16",
      "last_synced_at": "2026-10-16T07:12:03.869Z",
      "location_count": 40,
      "location_summary": "Birmingham, Alabama • Sacramento, California • San Diego, California + 37 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04594707"
    },
    {
      "nct_id": "NCT02370693",
      "title": "Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Diseases, Interstitial",
        "Systemic Sclerosis",
        "Scleroderma"
      ],
      "interventions": [
        {
          "name": "Bortezomib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate mofetil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2016-03",
      "completion_date": "2020-01-01",
      "has_results": true,
      "last_update_posted_date": "2021-08-25",
      "last_synced_at": "2026-10-16T07:12:03.869Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02370693"
    },
    {
      "nct_id": "NCT05241275",
      "title": "Xenon MRI and Progressive ILD",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Idiopathic Pulmonary Fibrosis",
        "Progressive Pulmonary Fibrosis"
      ],
      "interventions": [
        {
          "name": "Hyperpolarized 129 Xenon Gas Comparing Progressive Pulmonary Fibrosis Treatment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2022-07-19",
      "completion_date": "2026-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-11",
      "last_synced_at": "2026-10-16T07:12:03.869Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05241275"
    },
    {
      "nct_id": "NCT01055730",
      "title": "The Impact of Pulmonary Rehabilitation in Interstitial Lung Disease",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Interstitial Lung Disease"
      ],
      "interventions": [
        {
          "name": "Pulmonary rehabilitation",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2010-02",
      "completion_date": "2013-01",
      "has_results": false,
      "last_update_posted_date": "2013-11-21",
      "last_synced_at": "2026-10-16T07:12:03.869Z",
      "location_count": 5,
      "location_summary": "Concord, California • Daly City, California • New Haven, Connecticut + 2 more",
      "locations": [
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Daly City",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Falls Church",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01055730"
    },
    {
      "nct_id": "NCT06265532",
      "title": "Collagen-targeted Positron Emission Tomography (PET) Imaging for Assessment of EGCG Effect",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Idiopathic Pulmonary Fibrosis"
      ],
      "interventions": [
        {
          "name": "EGCG 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo for EGCG 300 mg",
          "type": "DRUG"
        },
        {
          "name": "EGCG 600 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo for EGCG 600 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hal Chapman",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "40 Years to 85 Years"
      },
      "enrollment_count": 12,
      "start_date": "2024-02-07",
      "completion_date": "2026-01-08",
      "has_results": false,
      "last_update_posted_date": "2026-04-14",
      "last_synced_at": "2026-10-16T07:12:03.869Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • Ann Arbor, Michigan • Charlottesville, Virginia",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06265532"
    },
    {
      "nct_id": "NCT02758808",
      "title": "Pulmonary Fibrosis Foundation Patient Registry",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Interstitial Lung Disease (ILD)",
        "Idiopathic Pulmonary Fibrosis (IPF)"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Pulmonary Fibrosis Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 2004,
      "start_date": "2016-03-29",
      "completion_date": "2022-12-16",
      "has_results": false,
      "last_update_posted_date": "2023-07-07",
      "last_synced_at": "2026-10-16T07:12:03.869Z",
      "location_count": 42,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 35 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02758808"
    }
  ]
}